top of page
  • Recruiting

NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T

  • NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy


Pembrolizumab


Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy


This phase II trial studies the effect of pembrolizumab in treating patients with multiple myeloma that is growing, spreading, or getting worse (progressing) on chimeric antigen receptor (CAR)-T cell therapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.


Sponsor:

Emory University


Collaborators:

Merck Sharp & Dohme LLC

National Cancer Institute (NCI)


Location

United States, Georgia

 

ClinicalTrials.gov Identifier: NCT05204160


Official Title: Phase II Study of Pembrolizumab as Salvage Therapy Among Multiple Myeloma Patients Progressing on CAR-T Cell Therapy


First Posted: January 24, 2022


Click here for details on ClinicalTrials.gov

 

Biological: Pembrolizumab

 

Keytruda

Lambrolizumab

MK-3475

Pembrolizumab

PEMBROLIZUMAB

SCH 900475











Comments


Posts Archive
bottom of page